AAAAAA
Results: 1-25/30
Authors:
Parnetti, L
Lanari, A
Amici, S
Gallai, V
Vanmechelen, E
Hulstaert, F
Citation: L. Parnetti et al., CSF phosphorylated tau is a possible marker for discriminating Alzheimer'sdisease from dementia with Lewy bodies, NEUROL SCI, 22(1), 2001, pp. 77-78
Authors:
Sjogren, M
Davidsson, P
Gottfries, J
Vanderstichele, H
Edman, A
Vanmechelen, E
Wallin, A
Blennow, K
Citation: M. Sjogren et al., The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process, DEMENT G C, 12(4), 2001, pp. 257-264
Authors:
Sjogren, M
Gisslen, M
Vanmechelen, E
Blennow, K
Citation: M. Sjogren et al., Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment, NEUROSCI L, 314(1-2), 2001, pp. 33-36
Authors:
Hesse, C
Rosengren, L
Andreasen, N
Davidsson, P
Vanderstichele, H
Vanmechelen, E
Blennow, K
Citation: C. Hesse et al., Transient increase in total tau but not phospho-tau in human cerebrospinalfluid after acute stroke, NEUROSCI L, 297(3), 2001, pp. 187-190
Authors:
Hemmer, K
Fransen, L
Vanderstichele, H
Vanmechelen, E
Heuschling, P
Citation: K. Hemmer et al., An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha, NEUROCHEM I, 38(7), 2001, pp. 557-565
Authors:
Vanmechelen, E
Vanderstichele, H
Hulstaert, F
Andreasen, N
Minthon, L
Winblad, B
Davidsson, P
Blennow, K
Citation: E. Vanmechelen et al., Cerebrospinal fluid tau and beta-amyloid((I-42)) in dementia disorders, MECH AGE D, 122(16), 2001, pp. 2005-2011
Authors:
Andreasen, N
Gottfries, J
Vanmechelen, E
Vanderstichele, H
Davidsson, P
Blennow, K
Rosengren, L
Blennow, K
Citation: N. Andreasen et al., Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease, J NE NE PSY, 71(4), 2001, pp. 557-558
Authors:
Sjogren, M
Davidsson, P
Tullberg, M
Minthon, L
Wallin, A
Wikkelso, C
Granerus, AK
Vanderstichele, H
Vanmechelen, E
Blennow, K
Citation: M. Sjogren et al., Both total and phosphorylated tau are increased in Alzheimer's disease, J NE NE PSY, 70(5), 2001, pp. 624-630
Authors:
Sjogren, M
Vanderstichele, H
Agren, H
Zachrisson, O
Edsbagge, M
Wikkelso, C
Skoog, I
Wallin, A
Wahlund, LO
Marcusson, J
Nagga, K
Andreasen, N
Davidsson, P
Vanmechelen, E
Blennow, K
Citation: M. Sjogren et al., Tau and A beta 42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values, CLIN CHEM, 47(10), 2001, pp. 1776-1781
Authors:
Andreasen, N
Minthon, L
Davidsson, P
Vanmechelen, E
Vanderstichele, H
Winblad, B
Blennow, K
Citation: N. Andreasen et al., Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice, ARCH NEUROL, 58(3), 2001, pp. 373-379
Authors:
Blennow, K
Davidsson, P
Vanmechelen, E
Citation: K. Blennow et al., CSF markers for early Alzheimer's disease, ALZHEIMER'S DISEASE, 2001, pp. 275-283
Authors:
Vanmechelen, E
Van Kerschaver, E
Blennow, K
De Deyn, PP
Galasko, D
Parnetti, L
Sindic, CJM
Arai, H
Riemenschneider, M
Hampel, H
Pottel, H
Valgaeren, A
Hulstaert, F
Vanderstichele, H
Citation: E. Vanmechelen et al., CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies, ALZHEIMER'S DISEASE, 2001, pp. 285-291
Authors:
Vanderstichele, H
Van Kerschaver, E
Hesse, C
Davidsson, P
Buyse, MA
Andreasen, N
Minthon, L
Wallin, A
Blennow, K
Vanmechelen, E
Citation: H. Vanderstichele et al., Standardization of measurement of beta-amyloid((1-42)) in cerebrospinal fluid and plasma, AMYLOID, 7(4), 2000, pp. 245-258
Authors:
Kumar-Singh, S
De Jonghe, C
Cruts, M
Kleinert, R
Wang, R
Mercken, M
De Strooper, B
Vanderstichele, H
Lofgren, A
Vanderhoeven, I
Backhovens, H
Vanmechelen, E
Kroisel, PM
Van Broeckhoven, C
Citation: S. Kumar-singh et al., Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease, HUM MOL GEN, 9(18), 2000, pp. 2589-2598
Authors:
Van Gool, SW
Van Kerschaver, E
Brock, P
Pottel, H
Hulstaert, F
Vanmechelen, E
Uyttebroeck, A
Van De Voorde, A
Vanderstichele, H
Citation: Sw. Van Gool et al., Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies, LEUKEMIA, 14(12), 2000, pp. 2076-2084
Authors:
Vanmechelen, E
Vanderstichele, H
Davidsson, P
Van Kerschaver, E
Van Der Perre, B
Sjogren, M
Andreasen, N
Blennow, K
Citation: E. Vanmechelen et al., Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, NEUROSCI L, 285(1), 2000, pp. 49-52
Authors:
Riemenschneider, M
Schmolke, M
Lautenschlager, N
Guder, WG
Vanderstichele, H
Vanmechelen, E
Kurz, A
Citation: M. Riemenschneider et al., Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline, NEUROSCI L, 284(1-2), 2000, pp. 85-88
Authors:
Sjogren, M
Minthon, L
Davidsson, P
Granerus, AK
Clarberg, A
Vanderstichele, H
Vanmechelen, E
Wallin, A
Blennow, K
Citation: M. Sjogren et al., CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J NEURAL TR, 107(5), 2000, pp. 563-579
Authors:
Raymackers, J
Daniels, A
De Brabandere, V
Missiaen, C
Dauwe, M
Verhaert, P
Vanmechelen, E
Meheus, L
Citation: J. Raymackers et al., Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization-mass spectrometry, nanoliquid chromatography-electrospray ionization-timeof flight-mass spectrometry, and tandem mass spectrometry, ELECTROPHOR, 21(11), 2000, pp. 2266-2283
Authors:
Ingelson, M
Blomberg, M
Benedikz, E
Wahlund, LO
Karlsson, E
Vanmechelen, E
Lannfelt, L
Citation: M. Ingelson et al., Tau immunoreactivity detected in human plasma, but no obvious increase in dementia, DEMENT G C, 10(6), 1999, pp. 442-445
Authors:
De Jonghe, C
Cras, P
Vanderstichele, H
Cruts, M
Vanderhoeven, I
Smouts, I
Vanmechelen, E
Martin, JJ
Hendriks, L
Van Broeckhoven, C
Citation: C. De Jonghe et al., Evidence that A beta 42 plasma levels in presenilin-1 mutation carriers donot allow for prediction of their clinical phenotype, NEUROBIOL D, 6(4), 1999, pp. 280-287
Authors:
De Jonghe, C
Cruts, M
Rogaeva, EA
Tysoe, C
Singleton, A
Vanderstichele, H
Meschino, W
Dermaut, D
Vanderhoeven, I
Backhovens, H
Vanmechelen, E
Morris, CM
Hardy, J
Rubinsztein, DC
St George-Hyslop, PH
Van Broeckhoven, C
Citation: C. De Jonghe et al., Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased A beta 42 secretion, HUM MOL GEN, 8(8), 1999, pp. 1529-1540
Authors:
Andreasen, N
Minthon, L
Vanmechelen, E
Vanderstichele, H
Davidsson, P
Winblad, B
Blennow, K
Citation: N. Andreasen et al., Cerebrospinal fluid tau and A beta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment, NEUROSCI L, 273(1), 1999, pp. 5-8
Authors:
Andreasen, N
Minthon, L
Clarberg, A
Davidsson, P
Gottfries, J
Vanmechelen, E
Vanderstichele, H
Winblad, B
Blennow, K
Citation: N. Andreasen et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, NEUROLOGY, 53(7), 1999, pp. 1488-1494
Authors:
Hulstaert, F
Blennow, K
Ivanoiu, A
Schoonderwaldt, HC
Riemenschneider, M
De Deyn, PP
Bancher, C
Cras, P
Wiltfang, J
Mehta, PD
Iqbal, K
Pottel, H
Vanmechelen, E
Vanderstichele, H
Citation: F. Hulstaert et al., Improved discrimination of AD patients using beta-amyloid((1-42)) and tau levels in CSF, NEUROLOGY, 52(8), 1999, pp. 1555-1562